Group 1 - The core viewpoint of the article highlights the financial performance and market position of BGM, indicating a mixed outlook with revenue growth but significant net loss [1] - As of July 29, BGM's stock opened at $10.33 per share, reflecting a 2.89% increase, with a total market capitalization of $1.9 billion [1] - Financial data shows that BGM's total revenue reached $1,431.14 million for the period ending March 31, 2025, representing a year-on-year growth of 13.92% [1] Group 2 - The company reported a net profit attributable to shareholders of -$86.12 million, which is a significant decrease of 307.79% compared to the previous year [1] - BGM, formerly known as Qilian International Holdings Group, is based in Chengdu, China, and focuses on innovative sectors such as biopharmaceuticals, biorefining, and healthcare [1] - The product range includes raw materials for oxytetracycline, licorice preparations, and crude heparin sodium, which are essential for both human pharmaceuticals and the global livestock industry [1]
博美集团上涨2.89%，报10.33美元/股，总市值19.00亿美元